caught in the window between mild illness and critical condition
Em 30 de março de 2022, a Anvisa abriu caminho para uma nova ferramenta no enfrentamento da COVID-19 no Brasil, autorizando em caráter emergencial o Paxlovid, da Pfizer — um antiviral oral destinado a adultos em risco de agravamento que ainda não precisam de hospitalização. A decisão unânime do colegiado reflete um esforço global de reguladores em múltiplos países para ampliar as opções terapêuticas disponíveis na janela crítica entre o adoecimento leve e o colapso clínico. Ainda assim, a aprovação regulatória e o acesso real permanecem distâncias distintas: o medicamento chega às farmácias privadas, enquanto o sistema público de saúde segue buscando seus próprios caminhos.
- O Brasil enfrentava em 2022 um cenário de opções terapêuticas limitadas para COVID-19, com oito medicamentos autorizados pela Anvisa, mas nenhum ainda incorporado ao SUS.
- A aprovação unânime do Paxlovid pela Anvisa sinalizou urgência regulatória, mas também impôs limites claros: grávidas, pacientes com insuficiência renal grave e hospitalizados com necessidade de oxigênio estão excluídos do uso.
- No mesmo dia, a Conitec votou pela recomendação do baricitinibe para o sistema público, criando uma divisão de estratégias — um antiviral para o setor privado, outro potencialmente para o público.
- A decisão final sobre o baricitinibe ainda dependia do Ministério da Saúde, deixando o acesso amplo à população mais vulnerável em compasso de espera.
- Enquanto o Paxlovid já estava autorizado nos EUA, Canadá, Reino Unido, Europa, China e Japão, sua chegada ao Brasil marcava um alinhamento global — mas sua disponibilidade real permanecia restrita a quem pode pagar.
Na quarta-feira, 30 de março de 2022, a Anvisa aprovou por unanimidade o uso emergencial do Paxlovid, antiviral da Pfizer, para adultos com COVID-19 que ainda não estão hospitalizados, mas correm risco de agravamento. O medicamento combina dois compostos — nirmatrelvir e ritonavir — em um tratamento de cinco dias, voltado para pacientes que respiram sem auxílio de oxigênio, mas cujo quadro clínico pode deteriorar rapidamente sem intervenção.
A autorização veio com restrições precisas: grávidas, pessoas com doença renal grave e pacientes já hospitalizados com necessidade de oxigênio ou ventilação mecânica não podem usar o medicamento. A diretora Meiruze Freitas reforçou que, apesar do avanço terapêutico, a vacinação continua sendo a principal barreira contra a doença grave e a morte.
No mesmo dia, a Conitec recomendou a incorporação do baricitinibe ao SUS, destinado a pacientes hospitalizados em uso de oxigênio ou ventilação não invasiva — um perfil distinto do público-alvo do Paxlovid. A decisão final, porém, cabia ao Ministério da Saúde, e ainda não havia sido tomada.
Assim, o Brasil chegava a um momento de expansão regulatória sem que isso se traduzisse imediatamente em acesso universal: o Paxlovid ficava disponível apenas em farmácias privadas, mediante prescrição médica, enquanto o caminho para tratamentos dentro do sistema público permanecia em aberto.
Brazil's health regulator cleared the way for Paxlovid on Wednesday, March 30th, granting emergency authorization for Pfizer's antiviral pill to treat COVID-19 in adults who are not yet hospitalized but face the risk of falling seriously ill. The decision came unanimously from Anvisa's board of directors, opening the door for patients to obtain the medication through pharmacies with a doctor's prescription.
The pill itself is a combination of two compounds—nirmatrelvir and ritonavir—taken over five days. It is intended for adults who are breathing on their own, without supplemental oxygen, but whose medical profile suggests they could deteriorate rapidly without intervention. The drug is not for everyone. Anvisa explicitly ruled it out for pregnant women, people with severe kidney disease or kidney failure, and patients already hospitalized and requiring oxygen or mechanical ventilation. These boundaries reflect the specific population the medication was designed to help: those caught in the window between mild illness and critical condition.
Meiruze Freitas, a director at Anvisa, emphasized that despite this new tool, vaccination remains the strongest defense against COVID-19 itself, as well as against hospitalization and death. Her statement underscored a reality that had become clear by early 2022: while treatments could help those already infected, prevention remained paramount. Paxlovid had already received emergency clearance in the United States, Canada, the United Kingdom, Mexico, across Europe, China, Australia, and Japan—a sign that regulators in multiple countries had reached similar conclusions about its safety and efficacy.
The approval in Brazil came as the country's health system was grappling with how to manage COVID-19 treatment more broadly. Anvisa had already authorized eight medications for the disease, though three of those had since been suspended. None had yet been incorporated into the public health system, the Sistema Único de Saúde, or SUS. On the same day Paxlovid was approved, however, a separate commission—the Conitec, responsible for evaluating new technologies for the public system—voted to recommend incorporating baricitinib, a different antiviral, into SUS. That medication would be reserved for hospitalized adults already on oxygen or non-invasive ventilation, a different patient population than Paxlovid targets.
The final decision on whether baricitinib would actually enter the public system rested with the Ministry of Health, a step that had not yet been taken. For now, Paxlovid remained available only through private pharmacies, accessible to those with prescriptions and the means to pay. The approval represented a regulatory milestone, but the path to making the treatment widely available across Brazil's public health infrastructure remained uncertain.
Citações Notáveis
Vaccination continues to be the best strategy to prevent COVID-19, hospitalizations, and deaths— Meiruze Freitas, Anvisa director
A Conversa do Hearth Outra perspectiva sobre a história
Why did Anvisa restrict Paxlovid to people not yet on oxygen? Why not give it to everyone sick enough to need hospitalization?
The drug was tested and shown to work best in that narrow window—sick enough to be at real risk, but not so far gone that their lungs are already failing. Once you're on oxygen, the infection has already progressed past where this particular pill can help. Different drugs for different stages.
So someone has to know they're getting worse before they can take it?
Exactly. A doctor has to recognize the signs—the patient who's struggling but still breathing room air, who has risk factors like age or other conditions. It's a judgment call, and it has to happen fast, within days of symptoms starting.
The article mentions baricitinib going into the public system. Is that better than Paxlovid?
Different tool. Baricitinib is for people already hospitalized, already on oxygen. Paxlovid is for catching it earlier, at home. If baricitinib actually gets approved by the Ministry, it helps the sicker patients. But Paxlovid helps prevent people from getting that sick in the first place.
Why is Paxlovid only in private pharmacies?
Because Anvisa approved it for emergency use, but the public health system hasn't decided to buy it yet. That's a separate process—the Conitec recommended baricitinib, but even that needs the Ministry to sign off. Public systems move slowly. Private pharmacies can stock it immediately.
Does that mean poor Brazilians can't access it?
For now, yes. Unless they can afford a private prescription and pharmacy price. That's the gap between regulatory approval and actual access—and it's a real one.